Citadel Advisors’s Pulse Biosciences PLSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$296K Buy
+13,700
New +$253K ﹤0.01% 10500
2025
Q2
Sell
-16,500
Closed -$265K 14490
2025
Q1
$265K Buy
16,500
+8,200
+99% +$153K ﹤0.01% 9855
2024
Q4
$145K Sell
8,300
-3,600
-30% -$63.5K ﹤0.01% 10944
2024
Q3
$209K Buy
11,900
+2,100
+21% +$35.8K ﹤0.01% 10056
2024
Q2
$110K Sell
9,800
-4,200
-30% -$39.6K ﹤0.01% 10784
2024
Q1
$122K Sell
14,000
-11,800
-46% -$108K ﹤0.01% 11084
2023
Q4
$316K Buy
25,800
+2,100
+9% +$14.5K ﹤0.01% 9060
2023
Q3
$95.5K Buy
+23,700
New +$147K ﹤0.01% 10955
2023
Q2
Sell
-45,700
Closed -$154K 15029
2023
Q1
$154K Buy
45,700
+25,100
+122% +$75.7K ﹤0.01% 10602
2022
Q4
$57.1K Sell
20,600
-11,800
-36% -$26.5K ﹤0.01% 11959
2022
Q3
$75K Buy
32,400
+13,500
+71% +$21.9K ﹤0.01% 11323
2022
Q2
$29K Buy
+18,900
New +$47.5K ﹤0.01% 12244
2022
Q1
Sell
-12,400
Closed -$184K 14347
2021
Q4
$184K Buy
+12,400
New +$247K ﹤0.01% 11972
2021
Q3
Sell
-22,600
Closed -$371K 14453
2021
Q2
$371K Sell
22,600
-2,300
-9% -$43.8K ﹤0.01% 10756
2021
Q1
$590K Buy
+24,900
New +$744K ﹤0.01% 9326

Other funds holding PLSE

Citadel Advisors's PLSE Position: Q1 2026 in Review

Citadel Advisors increased its Pulse Biosciences (PLSE) stake by 242% in Q1 2026, buying an estimated $1.86M and bringing the position to 142,150 shares worth $3.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5219.

Citadel Advisors first reported a position in PLSE in Q4 2017 and has held it in 15 quarters since. The position peaked at $7.97M in Q4 2017. 96 funds tracked by Wall St. Rank hold PLSE as of Q1 2026.

  • Citadel Advisors held 142,150 shares of Pulse Biosciences worth $3.07M as of Q1 2026.
  • Citadel Advisors bought 100,620 Pulse Biosciences shares in Q1 2026, an estimated $1.86M.
  • Pulse Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5219 holding.
  • Citadel Advisors first reported a position in Pulse Biosciences in Q4 2017 and has held it in 15 quarters since.
  • Citadel Advisors's Pulse Biosciences position peaked at $7.97M in Q4 2017.
  • 96 funds tracked by Wall St. Rank held Pulse Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.